A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer (PIKALO-3)
A Phase 2, Open-label, Randomized Study Investigating the Tolerability of Concurrent Versus Staggered Administration of Abemaciclib and Endocrine Therapy With Tersolisib in Patients With HR+, HER2- Node-Positive, PIK3CA-Mutated Early Breast Cancer.
The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation).
For each participant, the study will last up to 56 weeks and include 12 visits.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前：Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 電話番号：1-317-615-4559
- メール：LillyTrials@Lilly.com
研究連絡先のバックアップ
- 名前：Physicians interested in becoming principal investigators please contact
- メール：clinical_inquiry_hub@lilly.com
研究場所
-
-
California
-
Los Alamitos、California、アメリカ、90720
- Cancer and Blood Specialty Clinic
-
主任研究者：
- Sassan Farjami
-
-
Colorado
-
Lakewood、Colorado、アメリカ、80228
- USO - Rocky Mountain Cancer Centers
-
主任研究者：
- Sara Robinson
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Winship Cancer Institute, Emory University
-
主任研究者：
- Manali Bhave
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
主任研究者：
- Erica Mayer
-
-
Ohio
-
Columbus、Ohio、アメリカ、43212
- Stefanie Spielman Comprehensive Breast Center
-
主任研究者：
- Robert Wesolowski
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- Texas Oncology - West Texas
-
主任研究者：
- Ines Sanchez-Rivera
-
Austin、Texas、アメリカ、78731
- Texas Oncology - Balcones
-
主任研究者：
- Kathryn Hudson
-
San Antonio、Texas、アメリカ、78229-3307
- South Texas Accelerated Research Therapeutics (START)
-
主任研究者：
- Amita Patnaik
-
-
Virginia
-
Reston、Virginia、アメリカ、20190
- USO - Virginia Cancer Specialists
-
主任研究者：
- Isabelle Le
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Have histologically or cytologically confirmed breast cancer, defined as individuals with:
-
early stage, resected, invasive breast cancer without evidence of distant metastasis, and
-
have confirmed hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) status defined by
- Hormone Receptor (HR) status: documented estrogen receptor positive (ER+) and/or progesterone receptor+ tumor, defined as greater than or equal to (≥) 1% of tumor cells stained positive, assessed locally on primary disease specimen, as defined by American Society of Clinical Oncology College of American Pathologists (ASCO/CAP) Guidelines
- HER status: fulfill the requirement of HER2- disease by local testing on primary disease specimen; tumor must be HER2- according to ASCO/CAP guidelines for HER2 testing
-
-
Have evidence of an activating phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutation in tumor tissue.
-
Must have undergone definitive locoregional therapy, defined as surgery of the primary breast tumor(s), with or without radiation therapy, and/or systemic therapy (neo/adjuvant chemotherapy and or Endocrine Therapy (ET)) per standard guidelines.
-
Individuals with bilateral breast cancer (diagnosis of invasive tumors in both breasts simultaneously or within 6 months of each other) may be eligible if all lesions tested on both sides are HR+ HER2- and adequate surgery has been performed for both breasts.
-
Tumor involvement in at least 1 axillary lymph node (ALN).
-
≥ ipsilateral positive ALN, OR
-
1 to 3 ipsilateral positive ALN and either:
- tumor size ≥5cm, or
- histologic Grade 3 tumor (as defined by a combined score of at least 8 points per the modified Bloom-Richardson grading system or equivalent
-
-
Individuals must be randomized within 16 months from the time of definitive breast cancer surgery.
-
May have received up to 12 weeks of ET with AIs or tamoxifen until randomization following the last non-ET (surgery, chemotherapy, or radiation), whichever is last.
-
Are willing to follow contraception requirements.
Exclusion Criteria:
-
Have evidence of
- metastatic disease
- inflammatory breast cancer at primary breast cancer diagnosis
- breast cancer recurrence (local, regional, or distant), or
- a history of previous invasive breast cancer
-
Has an established diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus with Hemoglobin A1c (HbA1c) ≥8 percent (%), fasting plasma glucose ≥140 mg/dL (7.7 mmol/L), or requiring insulin.
-
Has a history of malignancy other than breast cancer
-
Have active Hepatitis B Virus (HBV)
-
Have active Hepatitis C Virus (HCV)
-
Have untreated Human Immunodeficiency Virus (HIV) infection
-
Have any other active systemic infection requiring system therapy
-
Have a history of Kaposi sarcoma or multicentric Castleman disease
-
Have a serious cardiac condition
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Arm A: Abemaciclib and Endocrine Therapy (ET) + Tersolisib - Staggered
Abemaciclib in combination with physician's choice of endocrine therapy (ET). Tersolisib will be added in a staggered approach after 2 cycles of abemaciclib and ET. All drugs will be administered orally. |
Administered orally Administered orally Administered orally Administered orally Administered orally
他の名前：
|
|
実験的：Arm B: Abemaciclib and Endocrine Therapy (ET) + Tersolisib - Concurrent
Abemaciclib and tersolisib will be administered concurrently in combination with physician's choice of ET. All drugs will be administered orally. |
Administered orally Administered orally Administered orally Administered orally Administered orally
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Rate of Participants who Discontinue Tersolisib Due to Treatment Emergent Adverse Events (TEAEs).
時間枠：Cycle 1 through study completion (estimated as 56 weeks)
|
Cycle 1 through study completion (estimated as 56 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of Exposure to Study Intervention
時間枠：Start of study intervention through study completion (estimated as 56 weeks)
|
Study intervention start is defined as Cycle -1 for Arm A and Cycle 1 for Arm B. Arm A includes an additional 8 weeks. |
Start of study intervention through study completion (estimated as 56 weeks)
|
|
Number of Study Intervention Dose Adjustments
時間枠：Start of study intervention through study completion (estimated as 56 weeks)
|
Study intervention start is defined as Cycle -1 for Arm A and Cycle 1 for Arm B. Arm A includes an additional 8 weeks. |
Start of study intervention through study completion (estimated as 56 weeks)
|
|
Pharmacokinetics (PK): Predose Plasma Concentrations (Cmax) of Tersolisib
時間枠：Day 15 through study completion (estimated as 56 weeks)
|
Day 15 through study completion (estimated as 56 weeks)
|
|
|
Change from Baseline in Side-Effect Burden as Measured by Functional Assessment of Cancer Therapy - General Item GP5 (FACT-GP5)
時間枠：Baseline to end of study completion (estimated as 56 weeks)
|
Baseline to end of study completion (estimated as 56 weeks)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター：Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 27842
- 2026-526410-87-00 (Ctis)
- J6M-MC-JSGH (その他の識別子：Eli Lilly and Company)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共有時間枠
Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD 共有アクセス基準
A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。